IM19 CAR-T cells / Beijing Imunopharm, Simcere 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo, IM19 CAR-T cells / Immunochina Pharma, Simcere
    Journal, CAR T-Cell Therapy:  A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. (Pubmed Central) -  Apr 1, 2022   
    Only one patient (4.5%) experienced grade 3 CRS and grade 3 neurotoxicity. These results demonstrated the safety and durable efficacy of a 4-1BB-based CD19 CAR-T, IM19, which is promising for further development and clinical investigation.
  • ||||||||||  IM19 CAR-T cells / Beijing Imunopharm, Simcere
    Trial completion date, Trial primary completion date, CAR T-Cell Therapy:  Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation (clinicaltrials.gov) -  Dec 17, 2020   
    P=N/A,  N=20, Recruiting, 
    These results demonstrated the safety and durable efficacy of a 4-1BB-based CD19 CAR-T, IM19, which is promising for further development and clinical investigation. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Dec 2021
  • ||||||||||  IM19 CAR-T cells / Beijing Imunopharm, Simcere
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date, CAR T-Cell Therapy:  Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T) (clinicaltrials.gov) -  May 20, 2019   
    P1/2,  N=177, Completed, 
    Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Dec 2021 Recruiting --> Completed | N=300 --> 177 | Trial completion date: Dec 2020 --> May 2019 | Trial primary completion date: May 2020 --> May 2019
  • ||||||||||  IM19 CAR-T cells / Beijing Imunopharm, Simcere
    Enrollment open, CAR T-Cell Therapy:  Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients (clinicaltrials.gov) -  Jul 16, 2018   
    P1,  N=30, Recruiting, 
    Recruiting --> Completed | N=300 --> 177 | Trial completion date: Dec 2020 --> May 2019 | Trial primary completion date: May 2020 --> May 2019 Not yet recruiting --> Recruiting
  • ||||||||||  IM19 CAR-T cells / Beijing Imunopharm, Simcere
    Phase classification, Enrollment change, CAR T-Cell Therapy:  Safety and Efficacy Evaluation of IM19 CAR-T Cells (clinicaltrials.gov) -  May 1, 2018   
    P1/2,  N=60, Recruiting, 
    Not yet recruiting --> Recruiting Phase classification: P1 --> P1/2 | N=20 --> 60
  • ||||||||||  IM19 CAR-T cells / Beijing Imunopharm, Simcere
    New P1 trial:  Safety and Efficacy Evaluation of IM19 Cells (clinicaltrials.gov) -  Nov 17, 2017   
    P1,  N=20, Recruiting,